ARS PHARMACEUTICALS INC. - COMMON STOCK

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

23 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

10 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with Type I Allergic Reactions Who Weigh 15 to 30 kg (33-66 lbs.)

09 Sep 2024 15:47:16 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

EURneffy (adrenaline nasal spray) Approved in the EU as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

26 Aug 2024 08:29:15 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

09 Aug 2024 11:49:53 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare Conference

07 Aug 2024 08:01:10 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial Results

06 Aug 2024 15:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Announces EURneffy (adrenaline nasal spray) Recommended for Approval by CHMP for Emergency Treatment of Allergic Reactions (anaphylaxis)

28 Jun 2024 05:30:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

09 May 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

30 Apr 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

03 Apr 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

21 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

07 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

26 Feb 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

22 Feb 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter

20 Feb 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting

05 Feb 2024 08:01:00 By Nasdaq GlobeNewswire

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 Nov 2023 15:00:00 By Nasdaq GlobeNewswire